82
Views
5
CrossRef citations to date
0
Altmetric
Case Report

Takayasu arteritis developing during treatment of ulcerative colitis with infliximab

, , , , , , , , , , , , , & show all
Pages 572-576 | Received 24 Apr 2012, Accepted 24 May 2012, Published online: 02 Jan 2014

REFERENCES

  • Numano F, Miyata T, Nakajima T. Ulcerative colitis, Takayasu arteritis and HLA. Intern Med. 1996;35:521–2.
  • Mekinian A, Néet A, Sibilia J, Cohen P, Connault J, Lambert M, et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford). 2012;51:882–6.
  • Tanaka F, Kawakami A, Iwanaga N, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and metho-trexate. Intern Med. 2006;45:313–6.
  • Maeda H, Handa N, Matsumoto M, Hougaku H, Ogawa S, Oku N, et al. Carotid lesions detected by B-mode ultrasonography in Takayasu's arteritis: "macaroni sign" as an indicator of the dis-ease. Ultrasound Med Biol. 1991;17:695–701.
  • Iizuka B, Yamagishi N, Honma N, Hayashi N. Cardiovascular diseases associated with ulcerative colitis. Nippon Rinsho. 1999;57:134-9. (in Japanese).
  • Horai Y, Miyamura T, Shimada K, Takahama S, Minami R, Yamamoto M, et al. A case of Takayasu's arteritis associated with human leukocyte antigen A24 and B52 following resolution of ulcerative colitis and subacute thyroiditis. Intern Med. 2011;50:151–4.
  • Morita Y, Yamamura M, Suwaki K, Mima A, Ishizu T, Hirohata M, et al. Takayasu's arteritis associated with ulcerative colitis; genetic factors in this association. Intern Med. 1996;35:574–8.
  • Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford). 2006;45:545–8.
  • Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296–304.
  • Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis. 2008;67:1567–9.
  • Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51:151–6.
  • Kteleh T, Khromachou T, Alfata S, Mouchli A. Despite existing treatment of etanercept and questionable paradoxical effect: case report and review of literature. J Med Cases. 2010;1:37–8.
  • Osman M, Aaron S, Noga M, Yacyshyn E. Takayasu's arteritis progression on anti-TNF biologics: a case series. Clin Rheumatol. 2011;30:703–6.
  • Guillevin L, Mouthon L. Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol. 2004;31:1885–7.
  • Numano F, Okawara M, Inomata H, Kobayashi H. Takayasu's arteritis. Lancet. 2000;356:1023–5.
  • Moreno D, Yuste J, Rodriguez M, Garcia-Velloso M, Prieto J. Positron emission tomography use in the diagnosis and follow up of Takayasu's arteritis. Ann Rheum Dis. 2005;64:1091–3.
  • Schmidt J, Kermani TA, Kirstin Bacani A, Crowson CS, Matte-son EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term follow-up. Arthritis Care Res (Hoboken). 2012.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.